Source comparison
TB-500 Study — Published Research Comparison
Equine Tendon Repair (2010, AJVR) 89 horses with SDFT injury 2.1 mg/100kg SC twice weekly × 6 weeks Return to racing 6.4 weeks earlier than controls (18.2 vs 24.6 weeks) Ultrasound fiber alignment scoring + performance tracking Gold standard for TB-500 tendon
This comparison does not assign a generated winner or score.
- Equine Tendon Repair (2010, AJVR)
- 89 horses with SDFT injury
- 2.1 mg/100kg SC twice weekly × 6 weeks
- Return to racing 6.4 weeks earlier than controls (18.2 vs 24.6 weeks)
- Ultrasound fiber alignment scoring + performance tracking
- Gold standard for TB-500 tendon efficacy. Largest veterinary trial with real-world functional endpoints
- Rodent Cardiac MI (2013, Circ Res)
- Adult male mice, LAD ligation
- 6 mg/kg IP at injury + 3 mg/kg twice weekly × 3 weeks
- 38% reduction in final infarct size (12.4% vs 20.1% LV mass)
- Histological planimetry + echocardiography
- Demonstrates TB-500's cardioprotective mechanism through reduced fibrosis and preserved contractility
- Human Corneal Defect (2015, Ophthalmology)
- 4 patients with persistent epithelial defects
- 0.1% solution (1 mg/mL), 1 drop 4× daily
- Complete closure in 14–21 days (defects non-healing 8–12 weeks prior)
- Fluorescein staining + slit lamp photography
- Case series only (no controls) but shows translational potential in human epithelial repair
- Diabetic Rat Wound (2012, WRR)
- STZ-diabetic rats, full-thickness excision
- 100 mcg topical in chitosan gel every 48h × 14 days
- 78% wound closure vs 52% in diabetic controls at day 14
- Digital planimetry + histology
- Significant finding: TB-500 partially overcomes diabetic healing impairment, approaching non-diabetic healing rates